HLA-C and neoplasm: After reinfusion in the patient’s circulation, the engineered TCRs exert cancer cell recognition through MHC protein binding, while CAR-T lymphocytes recognize tumor-associated antigens (TAAs) and trigger a cytotoxic immune response in an MHC-independent manner [135].